In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus.

As real world evidence (RWE) becomes a more prevalent resource for confirming and expanding product benefit-risk profiles, non-randomized studies (NRS) are emerging as a valuable generator of real world data (RWD). Joan Largent – Senior Director, Epidemiology and Outcomes Research at IQVIA – discusses the findings of her recent study and how researchers can utilize assessment tools for their ability to accurately assess NRS validity.

Mallinckrodt

Global biopharmaceutical company Mallinckrodt plc announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar Gel (repository corticotropin injection) in patients with refractory rheumatoid arthritis (RA) that did not adequately respond to standard-of-care therapies.

New global data analysis from Phesi shows the extent of the impact from the war in Ukraine on clinical development.

Regeneron and Sanofi announced that a late-stage trial for the blockbuster anti-inflammatory drug Dupixent for patients with chronic spontaneous urticaria (CSU) was halted due to futility.

Two-year follow-up data were reported from the Phase III CheckMate -9ER trial of Bristol Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) in the first-line treatment of advanced renal cell carcinoma.

Regeneron Pharmaceuticals Inc. on Feb. 4 reported fourth-quarter 2021 revenue that beat analysts’ estimates, boosted by demand for the blockbuster drugs Dupixent and Eylea, coupled with higher sales of the company’s COVID-19 therapy.

Pfizer Inc. and BioNTech SE said on Jan. 25 they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

The Biotechnology Innovation Organization (BIO) provides a glimpse of economic development in the biosciences ecosystem at the state and regional levels. The report, which was developed in partnership with the Council of State Bioscience Associations (CSBA), was released as an industry analysis in the wake of the COVID-19 pandemic and its impact on the overall economy. 

Merck & Co. said on November 26 updated data from the company’s study of the experimental COVID-19 pill molnupiravir showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.